INSOMNIA: OPTIMIZING OUTCOMES, IMPROVING LIVES

FACULTY

Andrew Krystal, MD, MS
Associate Professor of Psychiatry
Duke University School of Medicine
Director, Sleep Research Laboratory and Insomnia Program
Duke University Medical Center
Durham, North Carolina 

Read frequently asked questions submitted by your peers.

PURPOSE STATEMENT

This complimentary CME/CE program will discuss the impact of insomnia on patient functioning, including the presence of comorbid conditions, and will examine management strategies to improve patient quality of life.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Define insomnia and describe ways to identify patients in their practice who suffer from insomnia
• Discuss the effects of insomnia on patient functioning
• Describe the interrelationship of insomnia and comorbid medical and psychiatric disorders
• Describe and evaluate management options for insomnia, including new data from longer-term clinical trials

TARGET AUDIENCE

This enduring CME/CE series is intended for primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists, as well as for psychiatrists and other specialists and healthcare providers who are interested in the management of patients with insomnia.

ACCREDITATION INFORMATION

Expiration date: May 1, 2008

Physicians: Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses (CBRN): Med-IQ is a provider approved by the California Board of Registered Nursing, Provider Number CEP #14745, for 1.0 Contact Hours.

Pharmacists:

1 contact hours (0.100 CEUs) of credit for pharmacists. This activity co-sponsored by Medical Education Collaborative, Inc. (MEC) and Med-IQ. MEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE # 815-999-07-022-H01. The program is designed for all pharmacists.

                  

Other Credit Information
Nurse Practitioners: Med-IQ is accredited by ACCME to provide continuing medical education for physicians, and will provide nurse practitioners who successfully complete the activity with a Statement of Participation indicating that the activity was designated for 1 AMA PRA Category 1 Credit^TM.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit^TM for the PRA from organizations accredited by ACCME.

Disclosure Policy
It is the policy of Med-IQ that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentation(s). Individuals who refuse to disclose will be disqualified from all aspects associated with this CME activity. Med-IQ has policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

Andrew Krystal, MD, MS

Consulting fees/advisory boards:  sanofi-aventis U.S., GlaxoSmithKline, King Pharmaceuticals Inc., Merck & Co., Inc., Cephalon, Inc., Eli Lilly and Company, Neurocrine Biosciences, Sepracor, Pfizer, Inc., Johnson & Johnson, Organon Pharmaceutical USA Inc., Takeda Pharmaceuticals North America, Respironics, Inc., TransOral Pharmaceuticals, Inc., Neurogen Corporation, Somaxon Pharmaceuticals, AstraZeneca, Research Triangle Institute International, Novartis Pharmaceuticals
Fees received for promotional/non-CME activities: Sepracor, sanofi-aventis U.S.
Contracted research: sanofi-aventis U.S., GlaxoSmithKline, Merck & Co., Inc., Cephalon, Inc., Neurocrine Biosciences, Sepracor, Pfizer, Inc., Takeda Pharmaceuticals North America, Respironics, Inc., TransOral Pharmaceuticals, Inc., Neurogen Corporation, Somaxon Pharmaceuticals, Evotec

Med-IQ Disclosure
Reshma Carter has disclosed that her spouse is an employee of Novartis Pharmaceuticals.

All other employees of Med-IQ have no financial relationships to disclose.

MEC Disclosure
The employees of Medical Education Collaborative have no financial relationships to disclose.

Acknowledgement of Commercial Support
This educational series is supported by an educational grant from sanofi-aventis U.S.